Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ebola Response Funds From Congress, Gates Group Could Hasten Rapid Test Development

This article was originally published in The Gray Sheet

Executive Summary

The House FY 2015 federal spending continuing resolution would direct HHS and CDC to spend $88 million to deliver Ebola countermeasures, while Gates Foundation gives $50 million to the cause.

You may also be interested in...



U.S. Government Engages Dx Firms For Rapid, Field-Based Ebola Test

Multiple companies are receiving funding or are in discussions with federal agencies about development of rapid assays for Ebola that can be used by patients and health care workers in the field, a top official at the National Institute of Allergy and Infectious Diseases told "The Gray Sheet."

CDRH Funding Levels Frozen For Next Several Months

President Obama signed a continuing resolution measure that freezes FDA funding at fiscal year 2014 levels for the first two-and-a-half months of FY 2015. The bill keeps the government open, but it will hobble FDA’s ability to plan ahead and fill vacancies, advocates say.

FDA Puts Strengthened Emergency Authority To Use For Diagnostics

The agency’s diagnostic office is putting to the test new authority to grant emergency use authorization for a product before an emergency is officially declared, with an upcoming coronavirus test and a recently authorized flu test.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT033299

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel